(Total Views: 502)
Posted On: 09/11/2020 6:23:15 PM
Post# of 145247
Thanks, Ohm. Looks like RANTES is very much expressed in Myeloma. I'm brimming with ignorance in this field, but if you have time ever, look at this article about RANTES and Myeloma,
https://ashpublications.org/blood/article/112...-Chemokine
and this article about CCR5 and Myeloma,
https://pubmed.ncbi.nlm.nih.gov/15730850/
which has the conclusion "These data demonstrate that MIP-1alpha utilizes either CCR1 or CCR5 for its effects on OCL formation and myeloma cells, and that blocking either CCR1 or CCR5 inhibits OCL formation and myeloma cell adhesion to stromal cells."
So my uninformed guess is that Multiple Myeloma might well be a candidate for your list. Should I suggest to my friend that his dad's doctor check out Leronlimab? Pretty sure he wouldn't qualify for the Basket trial, because blook cancer must not be solid tumor cancer.
https://ashpublications.org/blood/article/112...-Chemokine
and this article about CCR5 and Myeloma,
https://pubmed.ncbi.nlm.nih.gov/15730850/
which has the conclusion "These data demonstrate that MIP-1alpha utilizes either CCR1 or CCR5 for its effects on OCL formation and myeloma cells, and that blocking either CCR1 or CCR5 inhibits OCL formation and myeloma cell adhesion to stromal cells."
So my uninformed guess is that Multiple Myeloma might well be a candidate for your list. Should I suggest to my friend that his dad's doctor check out Leronlimab? Pretty sure he wouldn't qualify for the Basket trial, because blook cancer must not be solid tumor cancer.
(1)
(0)